S

Sigachi Industries Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Sigachi Industries Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price34
Market cap₹995 Cr
P/E30.6
Updated26 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

4 of 4 strong

RevenueRank 2
MarginRank 1
CapexYes
FundraiseYes

Not discussed on this call: order book.

The short version

Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter. Revenue guidance for FY27 remains at INR650-675 crores, with quarter-on-quarter improvement expected.

From Sigachi Industries Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Rank 2
  • Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter.
  • Full-year revenue guidance remains INR650-675 crores, with expectations to reach INR160-170 crores in quarterly run rate by Q4 FY27.
  • Capacity expansion underway with debottlenecking and adding equipment to increase volumes beyond current 18,000 MT.
  • New capacities with Dahej 2 and CCS facility expected by FY28 to further increase volumes.
  • API segment revenues expected to ramp up from INR21 crores in Q1 to higher levels in subsequent quarters through new high-margin products.
  • Product mix improvements with co-processed excipients and differentiated products to enhance revenue and margins.
  • Export demand expected to remain key driver, especially in MCC and CCS segments.
  • Overall margin trajectory target is 18% EBITDA for the full year.

Profitability & Margins

See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • Ongoing capex for FY27 is around INR 100 crores, with an additional INR 150-200 crores planned for FY28.
  • Capex focuses on increasing capacity through debottlenecking, adding equipment (shifters, blenders), and product mix enhancements, especially in MCC.
  • New capacity expansions include increasing MCC capacity from 18,000 to 30,000 metric tons in upcoming quarters.
  • Dahej 2 plant expansion is progressing, expected operational by Q2 FY28 (delayed from earlier Q1 FY28 expectation).
  • CCS (Continuous Coating System) facility is expected to be fully operational in FY28.
  • Funding for capex may come from internal accruals, borrowings (bank finance/term loans), and potential preferential equity issuance.
  • Insurance claim (~INR16.5 crores) expected by September 2026 will support capex but delays won't hamper as alternate funding options exist.
  • Additional future capacity expansions are planned, with announcements forthcoming once finalized.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Sigachi Industries is currently receiving orders for the supply of CCS (Co-Processed Superdisintegrants) from export customers, even before the CCS production capacity is operational.
  • Inquiries are coming from foreign customers, likely due to market shortages and existing customer requirements for CCS alongside MCC.
  • The company expects more orders from exports once the CCS facility is operational (planned for FY28).
  • There is no explicit mention of overall current orderbook value or pending order backlog figures in the transcript.
  • Strong demand is indicated by inquiries and order interest despite current capacity bottlenecks.

Sigachi Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹117 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Sigachi Industries Ltd Q1 FY27 results?

Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter. Revenue guidance for FY27 remains at INR650-675 crores, with quarter-on-quarter improvement expected.

What is Sigachi Industries Ltd share price analysis?

Sigachi Industries Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sigachi Industries Ltd planning capital expenditure?

Ongoing capex for FY27 is around INR 100 crores, with an additional INR 150-200 crores planned for FY28.

Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.